YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Lyra Therapeutics (LYRA), announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis. The Company also announced a workforce…
Atara Biotherapeutics (ATRA) said Monday the US Food and Drug Administration is "unable" to approve PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
* Lyra Therapeutics press release [https://seekingalpha.com/pr/20304976-lyra-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (LYRA [https://seekingalpha.com/symbol/LYRA]): Q3 GAAP EPS of -$3.38 beat…
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.…
Dentsply International (XRAY) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.5 per share a year ago. These figures are adjusted for non-recurrin…
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics…
* Lyra Therapeutics press release [https://seekingalpha.com/pr/20198552-lyra-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]): Q2 GAAP EPS of -$5…
Investing.com - Lyra (NASDAQ: LYRA) reported second quarter EPS of $-5.510, $5.34 worse than the analyst estimate of $-0.170. Revenue for the quarter came in at $183K versus the consensus estimate of $242K. Lyra’s stock price closed at $6.…
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusi…
* Lyra Therapeutics (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]) registers 846,744 shares of common stock for resale by selling securityholders. * Shares are issuable upon exercise of outstanding warrants; company will receive proc…
Maria Palasis, President and CEO of Lyra Therapeutics, Inc. (NASDAQ:LYRA), sold 1565 shares of common stock on July 10, 2025, at a price of $8.91, for a total of $13944. The transaction occurred as the stock trades near $8.71, down roughly…
Lyra Therapeutics (NASDAQ:LYRA) Chief Financial Officer Jason Cavalier sold 684 shares of common stock on July 10, 2025, at a price of $8.91, for a total transaction value of $6,094. The sale comes as the stock trades near $8.71, down abou…
(RTTNews) - Lyra Therapeutics Inc. (LYRA) announced Friday a registered direct offering of 423,372 shares of common stock (or pre-funded warrants) priced at-the-market under Nasdaq rules, along with a concurrent private placement of warran…
Lyra Therapeutics (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]) announced that it will raise capital [https://seekingalpha.com/pr/20150434-lyra-therapeutics-announces-up-to-approximately-15-million-registered-direct-offering-and] th…
WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), currently trading at $13.38 with a market capitalization of $17.73 million, has secured approximately $5 million through a registered direct offering of common stock and warrants, a…
WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of…
[Markets up] Maxiphoto * Lyra Therapeutics (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]) is up ~376% in Monday trading after releasing phase 3 data on chronic rhinosinusitis candidate LYR-210. * The asset met its primary endpoint of…
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically signifi…
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improvemen…
WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of c…
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities for LYR-210 in CRS patient cohort with n…
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Lyra Therapeutics, Inc. (NASDAQ: LYRA) (“Lyra”) on behalf of the company’s investors. Since August 2022, shares of Lyra’s common stock have…
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhinosinusitis (CRS) patients who have had p…
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced…
STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Lyra…
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusi…
Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks Statistically significant improvements in efficacy were observed as early as 2 weeks Primary endpoint m…
WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announce…
WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of…
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline Results from BEACON Phase 2 Trial of LYR-…
Lyra Therapeutics WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhino…
WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), t…
Lyra Therapeutics WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of c…
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusi…
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), t…
Lyra Therapeutics WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhino…